Literature DB >> 9147009

Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods.

C E Smith1, B E Foleno, J F Barrett, M B Frosco.   

Abstract

Multidrug-resistant enterococci have become increasingly difficult to eradicate in a growing number of nosocomial infections. With the emergence of vancomycin-resistant enterococci, the use of synergistic antibiotic combinations has become one of the only remaining therapeutic options. Levofloxacin, the active l-isomer of ofloxacin, is a new oral and intravenous fluoroquinolone with a broad spectrum of activity against numerous Gram-positive, Gram-negative, and atypical organisms. The in vitro activity of levofloxacin, alone and in combination with ampicillin, against recent clinical isolates of Enterococcus faecium was assessed for synergistic interactions using the checkerboard agar dilution technique and time-kill methodology. Against all strains, the static technique of checkerboard agar dilution demonstrated indifferent or additive effects for the ampicillin + levofloxacin combination. With the dynamic time-kill technique, synergy was demonstrated for ampicillin (16 micrograms/ml) + levofloxacin (2 micrograms/ml) combination against three levofloxacin-sensitive, ampicillin-resistant isolates. At 24 h, the combination yielded a > or = 2-log10 decrease in CFU/ml compared to levofloxacin alone, while ampicillin had negligible effects. Against both a levofloxacin-intermediate, ampicillin-resistant isolate, and a highly levofloxacin-resistant, ampicillin-resistant isolate, none of the ampicillin+levofloxacin combinations tested demonstrated a synergistic interaction. The time-kill method suggested synergy for the ampicillin+levofloxacin combination against some strains of E. faecium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9147009     DOI: 10.1016/s0732-8893(96)00222-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.

Authors:  George Pankey; Deborah Ashcraft; Nalini Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  Epidemiol Infect       Date:  2010-08-09       Impact factor: 2.451

3.  Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.

Authors:  Federico Pea; Federica Pavan; Ennio Nascimben; Claudio Benetton; Pier Giorgio Scotton; Alberto Vaglia; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy.

Authors:  Nayara Helisandra Fedrigo; Danielle Rosani Shinohara; Josmar Mazucheli; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Frederico Severino Martins; Peijuan Zhu; Mingming Yu; Sherwin Kenneth B Sy; Maria Cristina Bronharo Tognim
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

5.  Purification and Characterization of an Active Principle, Lawsone, Responsible for the Plasmid Curing Activity of Plumbago zeylanica Root Extracts.

Authors:  Rajashree Bhalchandra Patwardhan; Prashant Kamalakar Dhakephalkar; Balu Ananda Chopade; Dilip D Dhavale; Ramesh R Bhonde
Journal:  Front Microbiol       Date:  2018-11-08       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.